Physician profile
Asheesh Tewari
NPI 1043248032
$203,657.97
in general payments reported to CMS, 2019-2025
16 companies · $25K in 2025
The $25K reported for 2025 was more than what 95% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $9,113 · 2021: $22K · 2022: $30K · 2023: $34K · 2024: $45K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $31K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Consulting Fee: $21K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Travel and Lodging: $7,346 · Honoraria: $3,000 · Food and Beverage: $2,189 · Gift: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $30,714.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,926.00 |
| Consulting Fee | $21,375.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,520.50 |
| Travel and Lodging | $7,345.69 |
| Honoraria | $3,000.00 |
| Food and Beverage | $2,189.17 |
| Gift | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dutch Ophthalmic, USA | $67,191.57 | 2019-2024 | Tissueblue, Eva, Combined Machine |
| Apellis Pharmaceuticals, INC. | $47,565.96 | 2022-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $42,194.67 | 2022-2025 | Ophthalmic Instruments, Xipere |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $27,148.17 | 2019-2021 | |
| Beaver-Visitec International, INC. | $7,500.00 | 2019 | |
| Allergan, INC. | $6,453.46 | 2019 | |
| Leica Microsystems INC. | $2,232.00 | 2021 | |
| Moria INC | $1,125.00 | 2021 | |
| Oculus Surgical INC. | $598.83 | 2022-2023 | |
| Dutch Ophthalmic Research Center (International) B.V. | $441.26 | 2023 | Tissueblue, Eva, Combined Machine |
| Genentech USA, INC. | $422.49 | 2019-2024 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $391.47 | 2019-2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $128.02 | 2019 | |
| Rxsight INC | $111.05 | 2022 | |
| Abbvie INC. | $81.60 | 2023-2024 | Ozurdex |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $72.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asheesh Tewari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.